Scilex Reports the Initiation of SP-103 in P-II Study for the Treatment of Acute Low Back Pain
Shots:
- The first patient has been dosed in the P-II study to evaluate the safety & efficacy of SP-103 in 80 patients with acute LBP. The study is expected to complete in 1yr. & was based on the favorable data from the PK study
- SP-103 has the same adhesion characteristics as cilex's marketed product ZTlido which includes label claims & enhanced adhesive qualities over competing products.
- Scilex’s triple-strength SP-103 is a non-aqueous lidocaine topical system that undergoes clinical development in acute LBP. Under the SPAC with Vickers, the combined company will be renamed Scilex & its common stock will be listed on Nasdaq with the ticker symbols “SCLX” & “SCLXW” & the transaction is expected to close in Q3’22
Ref: Globenewswire | Image: Scilex
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
